BSECompany Update24 Aug 2026 · 24 Aug 2026, 08:52 pm
Please find the enclosed intimation of the Company in relation to the captioned subject for reference.
AstraZeneca Pharma India Ltd · 506820
✦ AI SummaryESG
AstraZeneca Pharma India Ltd disclosed its ESG rating of 57 by Crisil ESG Ratings & Analytics Limited, based on publicly available information, without engaging the rating agency.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
AstraZeneca Pharma India Ltd - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Disclosure Of ESG Rating
Attachments (1)
📄pdf
Download →
7f29be45-2372-4894-9420-416a367a4573.pdf
View document text
August 24, 2026
The Manager – Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai 400001
The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051
Dear Sirs/ Madam
Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 – Disclosure of ESG Rating
With reference to the captioned subject, please note that Crisil ESG Ratings & Analytics Limited
(‘Crisil ESG Ratings’) has assigned an Environmental, Social, and Governance (‘ESG’) rating of 57 for
the Company based on publicly available information.
Please note that the Company has not engaged Crisil ESG Ratings. Crisil ESG Ratings has
independently prepared their reporting based on publicly available information of the Company.
Kindly take the above information on record.
Thanking you,
For AstraZeneca Pharma India Limited
Tanya Sanish
Company Secretary & Compliance Officer